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Abstract
In the past two years, several national and international bodies have made recommendations and
published updated practice guidelines for hepatitis B. In addition, new drugs have become available for
treatment of hepatitis B. This article will review the new recommendations for screening for hepatitis
B and for first-line antiviral medications to use for treatment. In addition, I will discuss the recent
recommendations on treating hepatitis B and human immunodeficiency virus co-infection and the
screening of people receiving immunosuppressive therapy.
Introduction and context
In the past two years, several important events have
focused attention on chronic hepatitis B virus (HBV)
infection in the US and elsewhere (Table 1). Three new
evidenced-based practice guidelines sponsored by regio-
nal liver societies have helped clarify HBV treatment
[1-3]. In addition, the Centers for Disease Control and
Prevention (CDC) recently publisheda recommendation
for the detection and management of chronic HBV [4],
and the National Institutes of Health held the first
Consensus Conference on Chronic HBV [5]. Also, a
treatment algorithm by American hepatologists and a
consensus of experts in Canada on treatment of hepatitis
B, both of which were funded by pharmaceutical
companies, were recently published [6,7]. Finally, the
Institute of Medicine has published a set of comprehen-
sive recommendations on HBV and HCV (hepatitis C
virus) in the US [8]. In the past 5 years, five new drugs for
treatment of HBV have been licensed in the US [1,9-13].
The following article will highlight the most important
points, from a clinician standpoint, that have come out
of these guidelines and conferences.
Recent advances
First of all, persons with chronic HBV cannot be
managed unless they have been identified. The vast
majority of chronically infected persons were born in
countries with a prevalence of hepatitis B surface antigen
(HBsAg) above 2% and include anyone born in Asia,
Africa, the South Pacific Islands, Eastern and Southern
Europe, and indigenous populations of Australia, New
Zealand, and the Arctic and parts of the Caribbean and
South America [4]. The CDC recommends that all
persons born in these regions be screened for HBsAg
and anti-HBs and that those found to be negative be
given hepatitis B vaccine. Other high-risk populations are
also outlined in the CDC report [4]. Currently, in the US,
most persons with chronic HBV are unidentified [4].
A study has shown that up to 65% of those newly found
by serosurveys to have HBV were unaware of their
infection status [14]. Another study has shown that less
than half of persons of Chinese descent in the US have
been tested for HBV [15].
Studies on the natural history of HBV in the past few
years have identified important risk factors for the
development of hepatocellular carcinoma (HCC) and
cirrhosis [16,17]. The REVEAL study from Taiwan, a
population-based study following over 3000 HBsAg-
positive persons for 11 years, found that in persons over
the age of 40, HBV DNA levels that are above 10
5 copies/
mL (20,000 IU/mL) at the beginning or end of an
11-year prospective follow-up are a significant risk factor
for both HCC and cirrhosis regardless of the ALT
(alanine aminotransferase) level [18,19]. This same
study showed that genotype C and basal core promoter
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DNA levels above 10
4 to 10
5 copies/mL and that in
persons over 40 years of age with all three risk factors, the
risk of HCC was 2% per year [20].
Updated evidenced-based guidelines for the manage-
ment of chronic HBV recommend that those persons
with moderate or severe liver necroinflammation or
fibrosis (which is often associated with elevated serum
liver enzyme levels) be treated for HBV [1-3]. For further
details, see the American Association for the Study of
Liver Diseases (AASLD) Practice Guideline on Chronic
Hepatitis B: 2009 Update or one of the other liver society
HBV practice guidelines listed in Table 1. Table 2 lists the
first- and second-line antiviral medications recom-
mended by all liver societies. The greatest detriment to
treating HBV is the development of antiviral resistance.
The consensus of guidelines is that the goal of treatment
should be complete suppression of HBV DNA to a level
undetectable by a polymerase chain reaction-based
assay. The alfa interferons have the advantage that
resistance does not develop to them and there is a limit
to the duration of treatment of not more than 1 year, but
only about 30% of patients respond to them [1,10].
Entecavir and tenofovir are potent nucleoside/tide
analogues that render most patients negative for HBV
DNA. These two drugs have a high barrier to resistance
and require more than one HBV mutation for resistance
to occur, so they are currently considered first-line drugs.
In contrast, lamivudine, telbivudine, and emtricitabine
require only one HBV mutation to occur for resistance to
develop and thus have a low barrier for resistance. The
rate of resistance occurrence between these three
antivirals is related to the potency of the drug, with
telbivudine being the most potent and lamivudine the
least. Adefovir is structurally related to tenofovir, is less
potent at the dosage licensed, and has a higher rate of
nephrotoxicity. Also, approximately 30% of persons
have a suboptimal response to adefovir [1,11].
For some time, the AASLD practice guideline for HCC
has recommended that persons with a family history of
HCC, those with cirrhosis, and males over 40 and
females over 50 with chronic HBV infection undergo
6-month surveillance for HCC to detect this cancer early.
The guideline recommends liver ultrasound as the
primary screening modality, but many clinicians include
alpha-fetoprotein testing as well [21].
Two other issues about treatment are worth mentioning.
First, HBV/HIV co-infection is not uncommon. A highly
active retroviral therapy (HAART) regimen that included
lamivudine as the only active drug against HBV may
adequately suppress HIV, but resistance to HBV will
likely develop in up to 90% of patients in 3-5 years [22].
Several studies have shown an increased rate of HBV
liver-related death in co-infected patients in whom both
viruses are not adequately suppressed [23]. A second
important issue is that, in the past decade, it has become
clear that reactivation of HBV with flares of hepatitis,
even fulminate leading to death, has occurred in patients
with chronic HBV infection who were administered
chemotherapy or other immunosuppressive drugs,
including tissue necrosis factor blockers. HBV reactiva-
tion was even reported in inactive HBsAg-positive
‘healthy’ carriers who had normal liver function tests
and who were negative for HBV DNA [24]. Controlled
trials and comparison studies have clearly shown that the
rate of exacerbation and flares of HBV can be reduced
from 50% in untreated persons to 10% if an antiviral
medication is given as prophylaxes started at the
beginning of chemotherapy and continued for 6 months
after completion [25].
Table 1. Recent Consensus Conferences and liver society guidelines on chronic hepatitis B
Conference/Guideline Year held/ published Download website report free
AASLD Chronic HBV 2009 Update 2009 http://www3.interscience.wiley.com/cgi-bin/fulltext/122523089/PDFSTART [1]
EASL HBV Guideline 2009 Update 2009 http://www.easl.eu/assets/application/files/f6fe13129b5f0df_file.pdf [3]
APASL HBV Guideline 2008 Update 2008 http://www.springerlink.com/content/du475u12q655175j/fulltext.pdf [2]
NIH Consensus Conference HBV 2008 http://consensus.nih.gov/2008/2008HepatitisBCDC120main.htm [26]
Recommendations Chronic HBV 2008 http://www.cdc.gov/mmWR/PDF/rr/rr5708.pdf [27]
IOM Report on HBV/HCV 2010 http://www.nap.edu/catalog.php?record_id=12793 [8]
AASLD, American Association for the Study of Liver Diseases; APASL, Asian Pacific Association for the Study of the Liver; EASL, European Association for
the Study of the Liver; HBV, hepatitis B virus; HCV, hepatitis C virus; IOM, Institute of Medicine; NIH, National Institutes of Health.
Table 2. Preferred antiviral medications for the treatment of
chronic hepatitis B
First-line medications
Interferon alfa 2/Pegulated interferon alfa
Entecavir
Tenofovir
Second-line medications
Lamivudine (3TC)
Adefovir dipivoxil
Telbivudine (LdT)
Medications licensed by the Food and Drug Administration but not
approved for hepatitis B virus
Emtricitabine (FTC)
Truvada (tenofovir + emtricitabine)
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The most important points for clinical practice are the
following:
1. Providers need to remember to screen their high-risk
patients for HBsAg and anti-HBs to identify persons with
chronic HBV who need management and to vaccinate
those who are negative with hepatitis B vaccine.
2. It is important for clinicians treating HBV to minimize
the risk of developing resistance while maximizing the
probability that patients will have an excellent response
to the antiviral medication chosen. Therefore, clinicians
should choose one of the first-line drugs listed in Table 2.
While there are advantages and disadvantages to all of
the first-line drugs such as cost, toxicity, and conve-
nience, it is difficult to recommend one drug over the
other and the decision of which first-line drug to use
should be left up to the physician and patient to decide.
3. High-risk HBV chronically infected persons should
undergo regular surveillance for HCC, as recommended
by AASLD practice guidelines.
4. If a clinician is treating HIV alone, they should use a
HAART combination of drugs that do not target HBV or,
if treating both infections, use a HAART regimen that has
at least two antivirals active against both viruses, either
tenofovir plus lamivudine or emtricitabine (Truvada
®;
Gilead Sciences, Inc., Foster City, CA, USA).
5. Before persons undergo chemotherapy or immuno-
suppressive therapy, they should be screened for HBV if
they belong to one of the high-risk groups. If found to be
HBsAg-positive, they should be administered antiviral
therapy from the time of initiation of chemotherapy or
immunosuppressive therapy until at least 6 months after
completion.
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